Clinical Trial Update: Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

View source ↗

Summary

A clinical trial update describes monitoring the response of cystic fibrosis lung disease to Orkambi using inhaled xenon MRI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Cystic Fibrosis | Status: ACTIVE_NOT_RECRUITING